Research VI on Pharmacovigilance and Risk Control During Clinical Trials of New Drugs: Suggestions for Improving the Supervision System of Pharmacovigilance and Risk Control During Clinical Trail of New Drugs

Zuo Xiaochun, Feng Hongyun, Zhi Huijing, Zhou Lingyun, Li Hao, Lü Xinhuan, Shao Ying, Yang Jianhong, Zhang Xianglin

Chinese Pharmaceutical Affairs ›› 2022, Vol. 36 ›› Issue (6) : 659-663.

Chinese Pharmaceutical Affairs ›› 2022, Vol. 36 ›› Issue (6) : 659-663. DOI: 10.16153/j.1002-7777.2022.06.008

Research VI on Pharmacovigilance and Risk Control During Clinical Trials of New Drugs: Suggestions for Improving the Supervision System of Pharmacovigilance and Risk Control During Clinical Trail of New Drugs

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2022, 36(6): 659-663 https://doi.org/10.16153/j.1002-7777.2022.06.008

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}

Accesses

Citation

Detail
Sections
Recommended
京ICP备17052540号-7
Copyright © Chinese Pharmaceutical Affairs, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉